Imaging biomarker validation for drug safety
4 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
International non-profit coordinating large-scale cancer clinical trials, immunoprofiling research, and patient outcome standardization across 39 countries.
“IB4SD-TRISTAN (coordinator, 2017-2024) validates PET and MRI imaging biomarkers for drug safety assessment in lung, rheumatology, and toxicology contexts.”
BE10 projects - MANCHESTER UNIVERSITY NHS FOUNDATION TRUST
Major NHS teaching hospital trust providing clinical patient access, rare disease expertise, and pregnancy safety data to European health research consortia.
“IB4SD-TRISTAN validates translational imaging methods (PET, MRI) for drug safety assessment in lung, rheumatology, and toxicology.”
UK9 projects - SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST
Major UK NHS teaching hospital providing clinical validation sites, patient cohorts, and real-world healthcare data for European digital health and medical research projects.
“IB4SD-TRISTAN validates translational imaging methods (PET, MRI) for detecting drug-induced toxicology in lung and rheumatology applications.”
UK7 projects - GE HEALTHCARE LIMITED
UK arm of GE Healthcare contributing PET/MRI imaging platforms and amyloid tracers to EU consortia on Alzheimer's imaging and drug-safety biomarker validation.
“Industrial partner in IB4SD-TRISTAN, validating translational PET/MRI biomarkers for lung, rheumatology and toxicology endpoints in drug development.”
PrimaryUK3 projects